Want to see HK:9960 full AI Analyst Report?
9960 Stock Chart & Stats
HK$1.17
HK$0.05(4.55%)
At close: 4:00 PM EST
HK$1.17
HK$0.05(4.55%)
Day’s Range― - ―
52-Week RangeHK$0.86 - HK$1.36
Previous CloseN/A
Volume114.00K
Average Volume (3M)183.14K
Market Cap
HK$931.99M
Enterprise Value-HK$560.72M
Total Cash (Recent Filing)HK$1.80B
Total Debt (Recent Filing)HK$394.97M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield10.61%
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,041,326,700
10 Day Avg. Volume75,400
30 Day Avg. Volume183,143
Financial Highlights & Ratios
PEG Ratio-6.54
Price to Book (P/B)0.37
Price to Sales (P/S)1.07
P/FCF Ratio22.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a sizable equity base provide financial resilience as the company manages its pressured operating results. This structure can reduce financing strain, preserve flexibility for laboratory investment, and improve its ability to withstand continued volatility in demand and profitability.
Improved Cash GenerationThe return to positive operating and free cash flow is an important improvement in the company’s ability to fund operations internally. If sustained, stronger cash conversion could support ongoing service delivery and investment without relying as heavily on external financing.
Solid Gross MarginA gross margin near 44% indicates that the underlying testing and diagnostic services retain meaningful economics before operating expenses. This provides a foundation for recovery if management can control the cost structure and convert gross profit into sustainable operating earnings.
Bears Say
Multi-Year Revenue DeclineThree consecutive years of revenue contraction indicate a sustained challenge in demand, pricing, or service volume rather than a single-period fluctuation. Continued top-line decline can reduce operating leverage, weaken market reach, and make a durable return to profitability more difficult.
Persistent LossesOngoing net losses and negative operating profit show that the company is not currently converting its clinical testing activities into acceptable overall returns. Persistent losses can consume financial resources, constrain reinvestment, and reduce the resilience of earnings through the next several quarters.
Volatile Cash FlowAlthough 2025 cash flow improved, the preceding pattern of negative free cash flow demonstrates that cash generation has not yet become dependable. Continued volatility could limit internally funded growth, complicate capital allocation, and weaken confidence in the durability of the latest improvement.
Kindstar Globalgene Technology, Inc. News
9960 FAQ
What was Kindstar Globalgene Technology, Inc.’s price range in the past 12 months?
Kindstar Globalgene Technology, Inc. lowest stock price was HK$0.85 and its highest was HK$1.36 in the past 12 months.
What is Kindstar Globalgene Technology, Inc.’s market cap?
Kindstar Globalgene Technology, Inc.’s market cap is HK$931.99M.
When is Kindstar Globalgene Technology, Inc.’s upcoming earnings report date?
Kindstar Globalgene Technology, Inc.’s upcoming earnings report date is Mar 26, 2027 which is in 145 days.
How were Kindstar Globalgene Technology, Inc.’s earnings last quarter?
Kindstar Globalgene Technology, Inc. released its earnings results on Aug 26, 2026. The company reported -HK$0.022 earnings per share for the quarter.
Is Kindstar Globalgene Technology, Inc. overvalued?
According to Wall Street analysts Kindstar Globalgene Technology, Inc.’s price is currently Overvalued.
Does Kindstar Globalgene Technology, Inc. pay dividends?
Kindstar Globalgene Technology, Inc. pays a Annually dividend of HK$0.095 which represents an annual dividend yield of 10.61%. See more information on Kindstar Globalgene Technology, Inc. dividends here
What is Kindstar Globalgene Technology, Inc.’s EPS estimate?
Kindstar Globalgene Technology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kindstar Globalgene Technology, Inc. have?
Kindstar Globalgene Technology, Inc. has 1,041,326,700 shares outstanding.
What happened to Kindstar Globalgene Technology, Inc.’s price movement after its last earnings report?
Kindstar Globalgene Technology, Inc. reported an EPS of -HK$0.022 in its last earnings report. Following the earnings report the stock price went up 3.261%.
Which hedge fund is a major shareholder of Kindstar Globalgene Technology, Inc.?
Currently, no hedge funds are holding shares in HK:9960
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kindstar Globalgene Technology, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.85%
12-Months-Change
Fundamentals
Return on Equity
-1.56%
Trailing 12-Months
Asset Growth
0.26%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kindstar Globalgene Technology, Inc.
Kindstar Global (Beijing) Technology, Inc. is a prominent provider of highly specialized diagnostic services to healthcare institutions across China. Beyond just diagnostics, the company extends its expertise to support medical research, clinical drug trials, and translational medicine initiatives for a diverse client base, including individual practitioners, research organizations, various hospital types, and pharmaceutical firms. This broad service portfolio is underpinned by its extensive, state-of-the-art laboratory infrastructure, which encompasses disciplines such as flow cytometry, cytogenetics, medical genomics, molecular biology, hematopathology, mass spectrometry, pathology, clinical immunology, and microbiology, alongside dedicated scientific research labs. Kindstar Global offers a comprehensive range of diagnostic tests covering key areas like hematology (blood), oncology (tumor), and genetic disorders. Its capabilities also extend to diseases affecting the cardiovascular and cerebrovascular systems, infectious agents, and autoimmune conditions, supporting various medical specialties including internal medicine, surgery, gynecology, pediatrics, and numerous other clinical fields. Established in 2003, the company maintains its headquarters in Wuhan, China.
Technical Analysis
Jinxin Fertility Group Ltd.
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
JD Health International, Inc.
―
Concord Healthcare Group Co., Ltd. Class H
―